Bellevue Group Ag Voyager Therapeutics, Inc. Transaction History

Bellevue Group Ag

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 12, 2021	SELL	$3.94 - $5.44 $125,292 - $172,992	-31,800 Closed	0 $0
Q1 2021 May 12, 2021	SELL	$4.61 - $9.04 $12.4 Million - $24.2 Million	-2,680,283 Reduced 98.83%	31,800 $150,000
Q2 2020 Aug 13, 2020	SELL	$8.05 - $14.21 $96,600 - $170,520	-12,000 Reduced 0.44%	2,712,083 $34.2 Million
Q1 2020 May 14, 2020	BUY	$6.8 - $14.66 $134,640 - $290,268	19,800 Added 0.73%	2,724,083 $24.9 Million
Q4 2019 Feb 14, 2020	SELL	$12.82 - $16.85 $5,128 - $6,740	-400 Reduced 0.01%	2,704,283 $37.7 Million
Q3 2019 Nov 14, 2019	BUY	$16.31 - $28.29 $397,963 - $690,276	24,400 Added 0.91%	2,704,683 $46.5 Million
Q2 2019 Aug 14, 2019	BUY	$19.18 - $27.88 $51.4 Million - $74.7 Million	2,680,283 New	2,680,283 $73 Million
Q1 2019 May 15, 2019	SELL	$8.0 - $19.66 $223,200 - $548,514	-27,900 Closed	0 $0
Q4 2018 Feb 12, 2019	SELL	$8.59 - $18.05 $133,333 - $280,172	-15,522 Reduced 35.75%	27,900 $262,000
Q3 2018 Nov 13, 2018	BUY	$17.11 - $21.74 $453,415 - $576,110	26,500 Added 156.6%	43,422 $822,000
Q2 2018 Aug 07, 2018	BUY	$16.76 - $23.92 $283,612 - $404,774	16,922 New	16,922 $331,000

130

34.7M

39.7K

34.6K

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $219M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.